https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3915347/ 2014
Multi-Target-Directed Ligands and other Therapeutic Strategies in the Search of a Real Solution for Alzheimer’s Disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3942876/ 2014
Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099354/ 2014
Identification of Potential Herbal Inhibitor of Acetylcholinesterase Associated Alzheimer’s Disorders Using Molecular Docking and Molecular Dynamics Simulation
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4362786/ 2014
Medication Development for Agitation and Aggression in Alzheimer Disease: Review and Discussion of Recent Randomized Clinical Trial Design
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4879492/ 2015
A clinical trial to validate event-related potential markers of Alzheimer’s disease in outpatient settings
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4703712/ 2015
White Matter Lipids as a Ketogenic Fuel Supply in Aging Female Brain: Implications for Alzheimer’s Disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4872397/ 2016
Advanced brain aging: relationship with epidemiologic and genetic risk factors, and overlap with Alzheimer disease atrophy patterns
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4847235/ 2016
Role of transient receptor potential ankyrin 1 channels in Alzheimer’s disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4885828/ 2016
CB2 Cannabinoid Receptor As Potential Target against Alzheimer’s Disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5025475/ 2016
Vascular Dysfunction in a Transgenic Model of Alzheimer’s Disease: Effects of CB1R and CB2R Cannabinoid Agonists
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5297661/ 2016
Cannabidiol Modulates the Expression of Alzheimer’s Disease-Related Genes in Mesenchymal Stem Cells
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5289988/ 2017
In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer’s Disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5516350/ 2017
Drug candidates in clinical trials for Alzheimer’s disease